Switching from originator infliximab to biosimilar (PF-06438179/GP1111) in patients with inflammatory bowel disease (SWIFT-BS study)

Switching from originator infliximab to biosimilar (PF-06438179/GP1111) in patients with inflammatory bowel disease (SWIFT-BS study) - SWIFT-BS study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054833

Enrollment

100

Registered

2024-07-02

Start date

2024-07-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel disease (Ulcerative colitis, Crohn&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis) undergoing maintenance treatment with infliximab originator 2) Patients who have been definitively diagnosed with inflammatory bowel disease (Crohn's disease or ulcerative colitis) according to the Japanese diagnostic criteria 3) Patients aged 18 years or older (if under 20 years old, consent from a legal representative must also be obtained) 4) Patients scheduled to switch to infliximab biosimilar (PF-06438179/GP1111) 5) Patients who have obtained written consent for this study

Exclusion criteria

Exclusion criteria: No regulations

Design outcomes

Primary

Measure	Time frame
The continuation rate of infliximab biosimilar (PF-06438179/GP1111) at 56 weeks.	—

Countries

Japan

Contacts

Public ContactHiroki Tanaka

Sapporo IBD Clinic Director

hirokit@mtc.biglobe.ne.jp+81-11-213-0397

Outcome results